| 引用本文:宋旦哥1 谭 萍2 史 华2.养正消积胶囊联合肝动脉化疗栓塞治疗对原发性肝癌患者肝功能改善的疗效观察[J].世界中医药,2013,8(08):. |
|
| 养正消积胶囊联合肝动脉化疗栓塞治疗对原发性肝癌患者肝功能改善的疗效观察 |
| Efficacy Observation of Yangzhengxiaoji Capsule Combined with Hepatic Artery Chemotherapy Embolism in Improving Liver Function in Patients with Primary Hepayic Carcinoma |
| 投稿时间：2013-07-05 |
| DOI：10.3969/j.issn.1673-7202.2013.08.042 |
| 中文关键词: 养正消积胶囊 原发性肝癌 肝功能 |
| English Keywords:Yangzhengxiaoji Capsule Primary Hepayic Carcinoma Liver function |
| 基金项目: |
|
| 摘要点击次数: 1319 |
| 全文下载次数: 1406 |
| 中文摘要: |
| 目的：观察养正消积胶囊联合肝动脉化疗栓塞对原发性肝癌患者肝功能的改善调节作用。方法：457例患者随机分成2组，232例口服养正消积胶囊（每次4粒，3次/d，饭后30 min温开水送服）+肝动脉灌注栓塞化疗(治疗组)，225例单用肝动脉灌注栓塞化疗（对照组），2组所用化疗药均为顺铂(DDP)+阿霉素(ADM)，疗程均为4周。结果：治疗组与对照组在治疗的有效率方面比较无统计学意义（P>0.05）；治疗组、对照组各指标治疗前后自身比较均有显著变化，有统计学意义（P<0.05），治疗组与对照组肝功能指标治疗前后比较，除PT外均有统计学意义（P<0.05）；治疗组与对照组比较未见明显不良反应。结论：养正消积胶囊联合肝动脉化疗栓塞治疗原发性肝癌患者肝功能指标的改善效果显著，未见明显不良反应，适合临床推广。 |
| English Summary: |
| To observe regulating effect of yangzhengxiaoji capsule on primary hepayic carcinoma patients treated by interventional hepatic artery perfusion embolism. Methods: A total of 457 patients were randomly divided into two groups. Treatment group: 232 cases of oral yangzhengxiaoji capsule， (four pieces at a time， three times a day， taken orally with warm water 30 min after meal) + hepatic artery chemotherapy embolism; control group: 225 cases that use hepatic artery chemotherapy embolism only. Medicine of both groups was DDP+ADM and the course lasted four weeks. Results: Treatment group and control group had no significant differences in treatment efficiency (P>0.05). The index before and after experiment in each group showed significant changes， and is of statistical significance (P<0.05）. Compared with control group， all liver function indicator in the treatment group， except for PT， all showed significant differences（P<0.05）. Treatment group showed no obvious adverse reactions compared with control group. Conclusion: Yangzhengxiaoji capsule with hepatic artery chemotherapy embolism is effective in improving liver function in patients with primary hepayic carcinoma. No obvious adverse reactions have been found thus is suitable for clinical application. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
